VolitionRx Limited (VNRX) — Analysis Summary
VolitionRx Limited (VNRX) has a market cap of $6.11M with year-over-year revenue growth of +40.0%. Net margin stands at -1352.2%. The stock trades at a P/E ratio of -0.2.
Key Takeaways
- Revenue changed +40.0% year-over-year
- Net margin of -1352.2%
- P/E ratio of -0.2
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, VNRX posted revenue growth of +40.0% and trades at a P/E of -0.2.
VolitionRx Limited (VNRX)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Current ratio at 0.30x — severe short-term liquidity risk
Operating margin at -791.2% — severe operating losses
Net margin at -1043.1% — losses exceed revenue (possible one-time charges)
Shareholder equity is negative, which can signal balance-sheet stress.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
75
Headquarters
HENDERSON, NV
Exchange
XASE
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.